185
Participants
Start Date
September 26, 2023
Primary Completion Date
June 1, 2027
Study Completion Date
June 1, 2028
STX-721 (Escalated)
STX-721 dose will be escalated per cBLRM-design.
STX-721 (3 dose levels)
Participants will receive STX-721 at one of two dose levels.
STX-721 (RP2D)
Participants will receive the RP2D of STX-721.
RECRUITING
Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis, Amsterdam
RECRUITING
Instituto de Investigacion Oncologica Vall dHebron (VHIO) - EPON, Barcelona
RECRUITING
National Taiwan University Hospital, Taipei
RECRUITING
Taipei Veterans General Hospital, Taipei
RECRUITING
Charité - Universitätsmedizin Berlin (CBF) - Hindenburgdamm 30, Berlin
RECRUITING
Thomas Jefferson University Research Facility, Philadelphia
RECRUITING
Hospital Universitario Ramon y Cajal, Madrid
RECRUITING
Chungbuk National University Hospital, Cheongju-si
RECRUITING
Hospital Regional Universitario de Malaga - Hospital General, Málaga
RECRUITING
Institut Claudius Regaud - PPDS, Toulouse
RECRUITING
SCRI Oncology Partners - PPDS, Nashville
RECRUITING
Hospital Universitario Virgen del Rocio, Seville
RECRUITING
EDOG Institut de Cancerologie de l'Ouest - PPDS, Saint-Herblain
RECRUITING
City of Hope, Duarte
RECRUITING
City of Hope, Irvine
RECRUITING
City of Hope, Huntington Beach
RECRUITING
Gustave Roussy, Villejuif
RECRUITING
Levine Cancer Institute - Charlotte, Charlotte
RECRUITING
University of Utah - Huntsman Cancer Institute - PPDS, Salt Lake City
RECRUITING
NEXT Virginia, Fairfax
RECRUITING
Universitätsklinikum Carl Gustav Carus an der TU Dresden, Dresden
Lead Sponsor
Antares Therapeutics, Inc
INDUSTRY